Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Stroke Blood Test That Could Increase Use of Most Effective Treatment Five-Fold

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
UNIGE in collaboration with Proteome Sciences describe a simple blood test.

Researchers at the University of Geneva (UNIGE), in collaboration with UK company Proteome Sciences plc (PS) describe a simple blood test that could substantially increase the number of patients eligible for highly effective ischaemic stroke therapy in a landmark paper “Blood Glutathione S-Transferase-π (GSTP) as a Time Indicator of Stroke Onset”, published in the journal PLoS ONE (

Ischaemic stroke (which accounts for around 85% of strokes) can only be treated effectively with the ‘clot busting’ drug, rt-PA, if administered within a time window of up to 4.5 hours after symptoms start in the UK (up to 3 hours in the US).

Approximately 35% of stroke victims are currently ineligible for treatment with rt-PA as they do not know the time of onset because the stroke occurs during sleep or the onset symptoms may not have been obvious.

This blood test enables doctors to determine the time window in which a stroke has occurred and could give many of these individuals access to this crucial treatment.

The University of Geneva study reports the outcome of a long-running trial of 29 blood proteins that Proteome Sciences and its partners have previously identified as early markers of brain damage associated with stroke.

In particular, the authors sought to identify readily available protein markers that help establish the time of onset of the stroke as an aid to select appropriate thrombolytic treatment.

This will be particularly useful in cases where patients do not know when the stroke occurred.

One protein, GSTP, showed an almost instantaneous increase in the blood of stroke patients, peaking at 3 hours after onset and returning to normal levels within approximately 6 hours.

Extrapolating the results of this study retrospectively across 555 patients who were admitted to the Geneva Hospital in 2006/7 with suspected stroke, but who did not know when their stroke symptoms started, indicates that testing for GSTP on all suspected stroke victims at admission, or preferably during initial assessment during transport to the hospital, could result in as many as five times more people being eligible for the highly effective rt-PA treatment for ischaemic stroke.

Leader of the study, Prof. Jean-Charles Sanchez, said: “This is a major step towards improving the management of ischaemic stroke patients using the drugs that we already have available. A simple blood test that matches the therapeutic window of rt-PA is a major advance that we encourage clinicians, pharmaceutical and diagnostics companies to unite to rapidly bring this into routine practice to improve patient outcomes.”

Dr Peter Coleman, Deputy Director of Research at The Stroke Association said: "When a stroke strikes time lost is brain lost, meaning that getting to hospital and receiving treatment quickly is absolutely essential. At the moment, suspected stroke patients should receive a brain scan as soon as possible to confirm which type of stroke they have had and determine the best treatment for them.

"A test such as this which could be used to quickly diagnose a stroke, possibly before a patient arrives at hospital, could speed up the treatment process and potentially improve outcomes. Stroke Association welcomes new technologies that can speed up diagnosis or improve diagnostic accuracy for people with a suspected stroke."

Dr. Ian Pike, Chief Operating Officer of Proteome Sciences, noted: “With a potential five-fold increase in the number of patients having access to the most effective form of ischaemic stroke treatment, this simple blood test will most importantly make the recovery time shorter and reduce the level of resulting disability for substantial numbers of stroke victims previously ineligible for drug therapy, whilst significantly reducing the cost of long term treatment and care.

“Following our license with Randox to develop a stroke test earlier this year, we expect to complete additional licenses with both diagnostic and pharmaceutical companies to ensure the technology is developed as quickly as possible to be used as a diagnostic tool for the use of rt-PA as a treatment.”

Dr. Alan Cookson, Licensing Officer from of UNIGE’s Technology Transfer Office UNITEC, commented “This breakthrough has been made possible through effective academic-industry partnership and provides an opportunity for utilization of innovation to secure both commercial value and potentially life-changing patient care benefits.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteome Sciences Extends its Reach Through Collaboration with MedBiomix Partners
Collaborative network alliance provide advanced data-driven solutions to integrate and make better use of protein expression data.
Wednesday, February 04, 2015
Appointment of Non-Executive Director
Company Board announces the appointment of Mr. Martin Diggle.
Friday, October 17, 2014
Proteome Sciences Signs $2m Contract with Genting TauRx Diagnostic Centre
Contract to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy.
Tuesday, September 30, 2014
Science and Technology Award for TMT at HUPO World Congress
TMT® chemical tags, distributed through Thermo Scientific, have become the global market leader.
Monday, September 15, 2014
Breakthrough Profiling Technology to Improve Cancer Treatment on a Personalized Basis
New research paper published in the peer reviewed journal PLOS ONE.
Saturday, April 12, 2014
Proteome Sciences Announces £5M Placing
Company conditionally places 17,857,143 new ordinary shares.
Monday, February 24, 2014
Proteome Sciences Appoints Director of Personalised Medicine
Proteome Sciences announces it has appointed Dr Chee Gee See as Director of Personalised Medicine with immediate effect.
Wednesday, October 30, 2013
Proteome Sciences to Develop Cancer Pathway Profiling Assays
New MS3 TMT® mass spectrometry technique to determine relative quantitation of proteins in multiple samples simultaneously.
Monday, June 17, 2013
In-vivo Study Shows CK1D Inhibitors Improve Cognition in Alzheimer’s Model
Proteome Sciences study shows improved cognition using its compounds.
Thursday, January 03, 2013
CK1D Development Update
Proteome Sciences has achieved further milestones in the development of inhibitors of the casein kinase 1 delta (CK1d) target in its Alzheimer's disease portfolio.
Tuesday, August 07, 2012
Stroke Biomarker License to Randox
Stroke biomarker to develop and produce diagnostic tests that could increase by fivefold the number of patients treated for stroke.
Friday, April 06, 2012
Completion of Alzheimer’s Plasma Biomarker Study
The preliminary results demonstrate significant diagnostic and prognostic utilities.
Wednesday, April 04, 2012
Scientific News
Resurrected Proteins Double Their Natural Activity
Researchers demonstrate method for reviving denatured proteins.
Scientists Decode Structure at Root of Muscular Disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
A Natural Light Switch
MIT scientists identify and map the protein behind a light-sensing mechanism.
Biologists Find Unexpected Role for Amyloid-Forming Protein
Yeast protein could offer clues to how Alzheimer’s plaques form in the brain.
Study Adds to Evidence That Viruses Are Alive
A new analysis supports the hypothesis that viruses are living entities that share a long evolutionary history with cells, researchers report.
How Flu Viruses Gain The Ability To Spread
New study reveals the soft palate is a key site for evolution of airborne transmissibility.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos